Articles Mentioning Healthcare Stocks

Results 1 - 10 of 220 : 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for Healthcare

Investing | April 02, 2014

Today’s Top Biotech Stories: MannKind, GSK, Myriad, and Alnylam

MannKind, GlaxoSmithKline, Myriad Genetics, and Alnylam Pharmaceuticals could all make waves in the biotech sector this morning.

Investing | March 12, 2014

Can Alexion Pharmaceuticals Continue to Deliver?

Alexion's valuation doesn't seem unreasonable relative to the significant sales growth opportunities still in front of the company

Investing | March 02, 2014

The Biggest S&P Winners So Far in 2014

The S&P 500 is at new records, and these stocks have been a big part of those gains. Find out more about these winning stocks here.

Investing | February 05, 2014

Valeant's Inorganic Growth Could Threaten These 3 Companies in 2014

Valeant just made its first acquisition of the year. Let’s take a closer look at three companies -- Allergan, Actavis, and Zeltiq -- which could be threatened by the company’s inorganic growth.

Investing | November 03, 2013

Is Abbott Labs Destined for Greatness?

Let's see what the numbers say about Abbott (ABT).

Investing | November 01, 2013

Medtronic's Plan to Reduce Hospital Readmissions

The Affordable Care Act is creating a variety of challenges and opportunities for health care companies. Medtronic is embracing a provision designed to reduce re-admissions by expanding into the home monitoring market.

Investing | October 23, 2013

Amarin, Cubist Pharmaceuticals, and Abaxis Could Be Big Movers Today

Keep an eye on Amarin, Cubist, and Abaxis -- they could make big moves during today's trading.

Investing | September 27, 2013

Regardless of Hype, Is There Still Upside in This Stock?

While this product is unquestionably remarkable, are you considering the risks before buying Pharmacyclics at inflated prices?

Investing | September 18, 2013

This Is One Incredible CEO

With a share price gain of more than 1,000% over the trailing 12 months, this company and its CEO are at the forefront of cracking a tough-to-treat disease.

Investing | July 18, 2013

Say Hello to the New Alkermes

Even biotechnology stocks could use a facelift now and then. Alkermes CEO Richard Pops outlines the new path his company will be taking moving forward.

Results 1 - 10 of 220 : 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for Healthcare